[Establishment and application of a drug screening model for anti-prostate cancer agents targeting androgen receptor].
暂无分享,去创建一个
Jinming Zhou | S. Cen | Jiwei Ding | Yang-guang Liu | Yang He | Xiaoyu Li
[1] F. Claessens,et al. Emerging mechanisms of enzalutamide resistance in prostate cancer , 2014, Nature Reviews Urology.
[2] Rikard Larsson,et al. The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer , 2014, Proceedings of the National Academy of Sciences.
[3] Gang Shao,et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.
[4] Joshua M. Korn,et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). , 2013, Cancer discovery.
[5] V. Arora,et al. Overcoming mutation-based resistance to antiandrogens with rational drug design , 2013, eLife.
[6] Zhongbo Liu,et al. Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy , 2012, Molecular carcinogenesis.
[7] Jinming Zhou,et al. Antiandrogenic, maspin induction, and antiprostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A. , 2012, Journal of medicinal chemistry.
[8] K. Iguchi,et al. Androgen receptor W741C and T877A mutations in AIDL cells, an androgen-independent subline of prostate cancer LNCaP cells , 2011, Tumor Biology.
[9] Shuifeng Qiu,et al. Salidroside induces cell-cycle arrest and apoptosis in human breast cancer cells. , 2010, Biochemical and biophysical research communications.
[10] H. Kung,et al. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. , 2010, Cancer research.
[11] H. Scher,et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.
[12] Clement Ip,et al. Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers , 2005, Molecular Cancer Therapeutics.